Novel 125I Uniformly Distributed Ophthalmic Plaques

Information

  • Research Project
  • 6404184
  • ApplicationId
    6404184
  • Core Project Number
    R43CA092913
  • Full Project Number
    1R43CA092913-01
  • Serial Number
    92913
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/2001 - 23 years ago
  • Project End Date
    6/30/2002 - 22 years ago
  • Program Officer Name
    STONE, HELEN B.
  • Budget Start Date
    9/1/2001 - 23 years ago
  • Budget End Date
    6/30/2002 - 22 years ago
  • Fiscal Year
    2001
  • Support Year
    1
  • Suffix
  • Award Notice Date
    8/20/2001 - 23 years ago

Novel 125I Uniformly Distributed Ophthalmic Plaques

DESCRIPTION (From the Applicant's Abstract): Brachytherapy seed eye plaques are commonly used in the treatment of ocular melanomas and macular degeneration. In addition to being relatively bulky, the dose distribution generated by the seed cores is non-uniform and highly complex. With the non-spherical iso-dose radiation profiles of each seed and variations in individual seed activities, it is an extremely involved and difficult process to accurately calculate the radiation dose rate at varying points within the eye and even within the tumor. A plan is proposed in which a novel uniformly distributed radioactive plaque is fabricated. The plaque shall consist of an 125I ion implanted thin foil attached to a 0.5 mm thick gold protective shield. The gold shield shall also act as a radiation collimator to protect normal structures located at the periphery of the plaque. A spacer will be used to seal the radioactive source. This plaque would provide accurate radiation dosimetry and would be three times thinner than current eye plaques. Tumor irradiation plans using such a plaque would optimize the dose to the tumor while minimizing the dose to normal ocular structures resulting in an significant decrease in radiation induced ocular complications. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    105526
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:105526\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    IMPLANT SCIENCES CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    WAKEFIELD
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    01880
  • Organization District
    UNITED STATES